AstraZeneca and Daiichi Sankyo's TROP2-targeting drug Datroway has been approved by the European Commission for some previously untreated patients with metastatic triple-negative breast cancer (TNBC), ...

The patient access system isn't broken because people wanted it to fail. It's broken because it was built for an era where the phone and fax machine were the only universal interfaces, and business ...

IGNYTE showed that patients with confirmed progression on an anti-PD-1-based regimen who received RP1 plus nivolumab had a 34% response rate, with a median duration of 24.8 months, and 15% of them ...

A woman from the Wirral in the UK has become the first patient in the world to receive an experimental cancer vaccine ...

According to a letter (PDF) signed by US Senators Elizabeth Warren (D-Mass), Angela Alsobrooks (D-Md), Richard Blumenthal ...

The European Society for Medical Oncology (ESMO) Annual Congress has long been a bellwether for global oncology trends, and the 2025 meeting in Berlin was no exception. This year’s event showcased a ...

Hogan Lovells partner Alice Valder Curran returned to join pharmaphorum editor-in-chief Jonah Comstock to elucidate some of ...

Anti-OX40L antibody amlitelimab was discarded as a treatment for atopic dermatitis last week, and today – during its ...

The European Commission has approved Otsuka's Dawnzera for the prevention of recurrent attacks in rare disease hereditary angioedema (HAE), a drug that can be self-administered by patients with weeks ...

FDA advisors have voted that Capricor Therapeutics has not provided strong evidence of efficacy for its cell therapy for ...

The once-daily, oral TEC/JAK3 inhibitor has shown efficacy in active and stable nonsegmental vitiligo (NSV) – the most common form of the disease – in which the most common form of vitiligo, ...

Otsuka is hoping to file for approval of its anti-APRIL antibody sibeprenlimab as a treatment for kidney disorder IgA nephropathy (IgAN) after the drug hit the target in a phase 3 trial. The Japanese ...